tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Biohaven Ltd. Files Prospectus for Share Resale

Story Highlights
  • Biohaven Ltd. filed a prospectus supplement for the resale of 3,588,688 common shares.
  • The Knopp Amendment replaces previous royalty obligations and reduces success-based payments, impacting financial commitments.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Biohaven Ltd. Files Prospectus for Share Resale

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Biohaven Ltd. ( (BHVN) ).

On August 15, 2025, Biohaven Ltd. filed a prospectus supplement for the resale of 3,588,688 common shares, which were issued as share consideration in connection with the Knopp Amendment. The amendment involves replacing previous royalty payment obligations with a flat mid-single digit royalty for BHV-7000 and pipeline programs, and reducing success-based payments by removing commercial sales-based milestones and lowering developmental and regulatory milestones to $210 million, with the company retaining the option to pay in cash or shares.

The most recent analyst rating on (BHVN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.

Spark’s Take on BHVN Stock

According to Spark, TipRanks’ AI Analyst, BHVN is a Underperform.

Biohaven Ltd.’s overall stock score is low due to substantial financial challenges, including zero revenue and negative cash flow. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. However, the recent $600 million investment provides a positive outlook by supporting clinical developments. Despite this, the overall risks remain significant, making the stock a cautious investment.

To see Spark’s full report on BHVN stock, click here.

More about Biohaven Ltd.

Biohaven Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is involved in creating treatments for neurological and neuropsychiatric diseases, with a particular emphasis on advancing its pipeline programs.

Average Trading Volume: 2,014,873

Technical Sentiment Signal: Sell

Current Market Cap: $1.51B

Find detailed analytics on BHVN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1